Hans Werner to Head InnoMed Technologies International Sales

Wednesday, May 15, 2002

Publication: Business Editors/Legal, Health & Medicine

InnoMed Technologies, Inc. is pleased to announce the addition of Hans J. Werner to its management team.
Mr. Werner has joined the company as Vice President, International Sales, and has over 10 years experience in the sales and marketing of Sleep Disordered Breathing and Non-Invasive Ventilation products to the International marketplace.

Mr. Werner comes to InnoMed from Vital Signs, Inc., (VITL-NYSE) where he served as President of the wholly owned subsidiary, Breas Medical AB (Sweden), and as President of Vital Signs International, Inc., responsible for $40 million in combined revenues. Prior experience includes a 12 year stay at Respironics Inc., (RESP-NYSE) where Mr. Werner last held the title of Director of International Sales, responsible for all of Europe, Africa, and the Middle East from 1988 to 1996, when sales in those markets reached $20 million.

Mr. Werner holds a Chemistry BA degree from the University of South Florida, a Materials Science Engineering M. Sc. degree from the University of Virginia, and an MBA from the University of Pittsburgh.

R. Patrick Karem, Chief Executive Officer comments: "We are pleased to have Hans join our growing company. With Hans having been in the industry since its early beginnings, the addition of him to our team will ensure International success commensurate with what we have already experienced in the U.S. marketplace."

InnoMed designs, manufactures, and markets the innovative NasalAire(TM) Nasal CPAP interface system. Independent clinical trials have shown that when patients are given a choice between using the Nasal Aire or the three leading competitive masks, manufactured by Resmed, Inc. (RMD-NYSE), Respironics (RESP-NASDAQ), and Mallinckrodt, 98% of the time the Nasal Aire was chosen.

InnoMed Technologies, Inc. is a 21st Century medical technologies company. The company is poised to bring new and more effective medical products and devices to the public through a medical development and engineering team, as well as acquisitions of other medical related companies. InnoMed Technologies, Inc. has primarily been a research oriented, privately held, medical technology development company. The company owns two full utility patents and patents pending. More information regarding InnoMed Technologies is available at http://www.innomedinc.com.

A Private Securities Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in written statements to be made) contain statements that are forward-looking, such as those relating to consummation of the transaction, anticipated future revenue of the Company, and success of current public offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ materially from those expressed in any forward looking statements.